Mouse Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ELISA Kit

VEGFR2, also known as KDR or Flk-1, is the type II transmembrane tyrosine kinase receptor that mediates VEGF-A-driven angiogenesis, vascular permeability, and endothelial cell proliferation. Mouse models of tumor neovascularization, ischemic tissue repair, anti-angiogenic drug screening, and developmental vasculogenesis routinely require quantification of VEGFR2 levels to evaluate pathway activity. The Mouse VEGFR2 ELISA Kit from Assay Genie is a quantitative immunoassay configured for 96 assays on a standard microplate, enabling measurement of VEGFR2 across multiple mouse specimen types.

Each kit accommodates multiple specimen matrices, including tissue homogenates prepared from mouse organs, plasma, and serum samples, so investigators can probe receptor abundance directly in target tissues rather than depending on circulating markers alone. The 96-assay plate layout supports medium-throughput experimental designs such as time-course studies, dose-response evaluation of candidate kinase inhibitors, or comparative profiling across transgenic and wild-type littermate controls. The procedure follows standard incubation and wash steps and produces an absorbance-based signal that can be read on a conventional microplate reader, with all required reagents, buffers, and a pre-coated plate supplied for a complete workflow.

KDR Flk-1 mouse VEGFR2 immunoassay kit from Assay Genie is intended for research use only and is not cleared or approved for diagnostic procedures. Storage is recommended under refrigerated conditions until first use, with components stable through the printed expiration when the protocol is followed; equilibrate reagents to room temperature before opening vials, and avoid repeated freeze-thaw cycles of reconstituted standards or samples to preserve antibody binding activity. Researchers working with VEGF-pathway inhibitors, endothelial-specific conditional knockout models, or therapeutic angiogenesis programs commonly pair this plate-based readout with orthogonal methods such as Western blot, immunohistochemistry, or flow cytometry to confirm functional consequences of VEGFR2 modulation.